Averell CM, et al. - Researchers compared patients with asthma taking the once-daily inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fluticasone furoate/vilanterol (FF/VI) vs the twice-daily ICS/LABAs budesonide/formoterol (B/F) and fluticasone propionate/salmeterol (FP/SAL), in terms of medication adherence and persistence in this real-world observational analysis. They used IQVIATM Health Plan Claims Data and examined patients with asthma ≥ 18 years of age starting ICS/LABA therapy with FF/VI, B/F, or FP/SAL between January 1, 2014 and June 30, 2016 (index date), in this retrospective cohort study. They matched 3,764 and 3,339 patients taking FF/VI to patients taking B/F or FP/SAL, respectively, following propensity score matching. Findings revealed better adherence and lower risk of treatment cessation in patients starting FF/VI vs B/F or FP/SAL in this real-world study, this implies possible improvement in adherence and persistence with once-daily ICS/LABA treatment vs twice-daily alternatives.